Jefferies analyst Kelly Shi assumed coverage of 4D Molecular with a Buy rating with a price target of $58, up from $30. The firm likes 4D Molecular’s proprietary platform which allows high-performing viral vectors to target broad therapeutic areas and highlights wet Age-Related Macular Degeneration/Diabetic Macular Edema asset 4D-150 with differentiated safety/efficacy in Phase 2 and thinks 4D-710 in cystic fibrosis can target a multi-billion dollar market with very meaningful initial data viewed by key opinion leaders, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular announce update on regulatory interactions, development for 4D-710
- 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
- 4DMT to Participate in Upcoming Investor Conferences
- 4DMT Reports Full Year 2023 Financial Results and Operational Highlights
- 4D Molecular presents interim data from 4D-310 INGLAXA Phase 1/2 trials
